Results - Announcements
Akums Drugs & Pharmaceuticals Ltd share price softened by 0.05% to Rs 731.5. The Company's net profit improved by 13.46% to Rs 114.57 crore, while revenue from operations edged up 15.07% to Rs 1342.39 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, easing 4.75%. It has marginally improved by 2.16% over last one week and moved up slightly by 0.86% in last one month while the market capitalization of Akums Drugs & Pharmaceuticals Ltd has inched up 1.83% and 9.83% in the same period respectively.
Profit before tax (PBT) of Akums Drugs & Pharmaceuticals Ltd stood at Rs 154.74 crore in Q3 FY26, surging by 135.63% year-on-year, and improving 11.13% quarter-on-quarter. EBITDA came in at Rs 166 crore, rallying 167.02% YoY and advancing by 14.91% sequentially.
Total expenses went up by 15.28% to Rs 1190.87 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 719.46 crore, posting a minor increase of 5.47% YoY, while employee benefits expense was at Rs 224.27 crore, improving by 11.34% YoY.
For the TTM ended FY26, revenue from operations inched higher 5.85% to Rs 4359.02 crore, while net profit witnessed a sharp fall of 25.42% to Rs 256.4 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 41246% to Rs 393.29 crore, and PBT rose 10.67% to Rs 382.1 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 1181.2 crore in FY26, as against Rs 465.2 crore in FY25.
Akums Drugs & Pharmaceuticals Ltd surged by 56.22% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 9.87% during the same period.